CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients

Recruiting now · Not applicable

Conditions studied: Management, Low Risk, Skin Cancer

In brief

Current clinical practices often provide general verbal advice to low-risk patients, which may not sufficiently address individual concerns or offer actionable steps. Generic information on the internet can be overwhelming or unreliable, leading to confusion and unnecessary follow-up visits. This project introduces a tailored approach by combining evidence-based guidelines with personalized details about the patient's risk profile. The discharge letter bridges the gap between clinical expertise and patient understanding, offering clear, specific, and actionable advice that has been shown to improve health behaviors and outcomes in other contexts . The personalized discharge letters are generated using an AI agent trained on validated letters from the hospital's electronic health record system (KWS). Each letter is reviewed and approved by a physician before being provided to the patient, ensuring both accuracy and clinical relevance.

Key facts

Study ID

NCT07330323

Run by

Universitaire Ziekenhuizen KU Leuven

People needed

150

Starts

2026-05-20

Expected to finish

2029-06-01

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
• Low-risk skin cancer patients:
• Negative personal history for melanoma
• Less than 100 naevi
• Less than 5 clinically atypical naevi
• Maximum 1 BCC in history
• Maximum 1 SCC, and at least 5 years ago
• AK: treated and controlled with clinical response
• M Bowen: treated and controlled with clinical response
• Adult subjects (between 18 years of age and 80 years) at time of enrolment

You may not qualify if…

• Presence of dermatological lesions requiring immediate treatment at the time of consultation.
• History of solid organ transplantation (Organ Transplant Recipient, OTR).
• Known carriers or suspected carriers (based on family history) of germline mutations associated with increased skin cancer risk (e.g. CDKN2A, PTCH1, XP genes).
• Failure to meet one or more of the inclusion criteria.
• Any condition or comorbidity that, in the opinion of the investigator, may interfere with study participation or data interpretation (e.g. severe cognitive impairment, language barrier).
• Participation in another interventional clinical trial that may interfere with the outcomes of this study.

Where it is running

• UZLeuven, Department of Dermatology — Leuven, Vlaams-Brabant, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.